

Claudio Ceconi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5449503/publications.pdf>

Version: 2024-02-01

142
papers

66,930
citations

30047

54
h-index

10724

138
g-index

152
all docs

152
docs citations

152
times ranked

51382
citing authors

#	ARTICLE	IF	CITATIONS
1	European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention and Rehabilitation (EACPR). European Heart Journal, 2012, 33, 1635-1701.	1.0	5,247
2	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	1.0	5,233
3	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2012, 33, 2569-2619.	1.0	5,034
4	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 2010, 31, 2369-2429.	1.0	4,635
5	Guidelines on the management of valvular heart disease (version 2012). European Heart Journal, 2012, 33, 2451-2496.	1.0	3,465
6	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	1.0	3,144
7	Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). European Heart Journal, 2009, 30, 2493-2537.	1.0	3,108
8	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	1.0	2,811
9	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	1.0	2,767
10	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2010, 31, 2501-2555.	1.0	2,649
11	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	1.2	2,558
12	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	1.0	2,447
13	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europace, 2012, 14, 1385-1413.	0.7	2,319
14	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	2.9	2,307
15	ESC Guidelines for the management of grown-up congenital heart disease (new version 2010): The Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC). European Heart Journal, 2010, 31, 2915-2957.	1.0	2,134
16	Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): The Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). European Heart Journal, 2009, 30, 2369-2413.	1.0	1,822
17	Guidelines for the diagnosis and management of syncope (version 2009): The Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). European Heart Journal, 2009, 30, 2631-2671.	1.0	1,784
18	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal, 2015, 36, 2921-2964.	1.0	1,768

#	ARTICLE	IF	CITATIONS
19	ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 3147-3197.	1.0	1,694
20	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2851-2906.	1.0	1,394
21	Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2010, 12, 1360-1420.	0.7	1,360
22	Guidelines on the management of valvular heart disease (version 2012). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S1-S44.	0.6	1,313
23	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812.	1.0	735
24	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>Europace</i> , 2010, 12, 1526-1536.	0.7	297
25	Therapeutic Effects of L-Carnitine and Propionyl-L-carnitine on Cardiovascular Diseases: A Review. <i>Annals of the New York Academy of Sciences</i> , 2004, 1033, 79-91.	1.8	208
26	Chromogranin A in heart failure. A novel neurohumoral factor and a predictor for mortality. <i>European Heart Journal</i> , 2002, 23, 967-974.	1.0	189
27	Oxidative Stress During Myocardial Ischaemia and Heart Failure. <i>Current Pharmaceutical Design</i> , 2004, 10, 1699-1711.	0.9	186
28	Tumor Necrosis Factor- α Receptor 1 Is a Major Predictor of Mortality and New-Onset Heart Failure in Patients With Acute Myocardial Infarction. <i>Circulation</i> , 2005, 111, 863-870.	1.6	185
29	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 1143-1153.	2.9	152
30	ACE inhibition with perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. <i>Cardiovascular Research</i> , 2007, 73, 237-246.	1.8	146
31	Oxidative stress in cardiovascular disease: myth or fact?. <i>Archives of Biochemistry and Biophysics</i> , 2003, 420, 217-221.	1.4	143
32	Heart failure and chronic obstructive pulmonary disease: the challenges facing physicians and health services. <i>European Heart Journal</i> , 2013, 34, 2795-2807.	1.0	141
33	Improved Exercise Tolerance After Losartan and Enalapril in Heart Failure. <i>Circulation</i> , 1998, 98, 1742-1749.	1.6	128
34	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	1.4	113
35	Apoptosis of Skeletal Muscle Myofibers and Interstitial Cells in Experimental Heart Failure. <i>Journal of Molecular and Cellular Cardiology</i> , 1998, 30, 2449-2459.	0.9	111
36	Enhanced Expression and Activity of Xanthine Oxidoreductase in the Failing Heart. <i>Journal of Molecular and Cellular Cardiology</i> , 2000, 32, 2083-2089.	0.9	110

#	ARTICLE	IF	CITATIONS
37	Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 147-157.	1.3	88
38	Potential Prognostic Significance of Decreased Serum Levels of TRAIL after Acute Myocardial Infarction. <i>PLoS ONE</i> , 2009, 4, e4442.	1.1	82
39	Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. <i>International Journal of Cardiology</i> , 2011, 146, 408-414.	0.8	80
40	Aorta and Skeletal Muscle NO Synthase Expression in Experimental Heart Failure. <i>Journal of Molecular and Cellular Cardiology</i> , 1996, 28, 2241-2248.	0.9	78
41	Angiotensin-converting enzyme (ACE) inhibitors have different selectivity for bradykinin binding sites of human somatic ACE. <i>European Journal of Pharmacology</i> , 2007, 577, 1-6.	1.7	75
42	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016, 18, 482-489.	2.9	74
43	Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease. <i>European Heart Journal</i> , 2010, 31, 1854-1864.	1.0	70
44	Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice. <i>Respirology</i> , 2012, 17, 422-431.	1.3	69
45	Cardiac troponin elevation predicts all-cause mortality in patients with acute exacerbation of chronic obstructive pulmonary disease: Systematic review and meta-analysis. <i>International Journal of Cardiology</i> , 2015, 191, 187-193.	0.8	69
46	Metabolic Adaptation During a Sequence of No-Flow and Low-Flow Ischemia. <i>Circulation</i> , 1996, 94, 2587-2596.	1.6	66
47	Occurrence of oxidative stress during myocardial reperfusion. <i>Molecular and Cellular Biochemistry</i> , 1992, 111, 61-69.	1.4	64
48	An imbalanced OPG/TRAIL ratio is associated to severe acute myocardial infarction. <i>Atherosclerosis</i> , 2010, 210, 274-277.	0.4	61
49	Efficacy of Ivabradine in Combination with Beta-Blocker Versus Uptitration of Beta-Blocker in Patients with Stable Angina. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 531-537.	1.3	61
50	Sensitivity, specificity, and predictive accuracies of non-invasive tests, singly and in combination, for diagnosis of hibernating myocardium. <i>European Heart Journal</i> , 2000, 21, 1358-1367.	1.0	58
51	Uric acid and coronary artery disease: An elusive link deserving further attention. <i>International Journal of Cardiology</i> , 2016, 213, 28-32.	0.8	57
52	Extraction and Assay of Creatine Phosphate, Purine, and Pyridine Nucleotides in Cardiac Tissue by Reversed-Phase High-Performance Liquid Chromatography. <i>Analytical Biochemistry</i> , 1994, 222, 374-379.	1.1	56
53	Long-term treatment with ivabradine in post-myocardial infarcted rats counteracts channel overexpression. <i>British Journal of Pharmacology</i> , 2012, 165, 1457-1466.	2.7	55
54	New insights on myocardial pyridine nucleotides and thiol redox state in ischemia and reperfusion damage. <i>Cardiovascular Research</i> , 2000, 47, 586-594.	1.8	54

#	ARTICLE	IF	CITATIONS
55	Tumor necrosis factor in congestive heart failure: A mechanism of disease for the new millennium?. <i>Progress in Cardiovascular Diseases</i> , 1998, 41, 25-30.	1.6	52
56	Chromogranin A and Tumor Necrosis Factor- α (TNF) in Chronic Heart Failure. , 2000, 482, 351-359.		50
57	Differences in the Effect of Angiotensin-converting Enzyme Inhibitors on the Rate of Endothelial Cell Apoptosis: In Vitro and In Vivo Studies. <i>Cardiovascular Drugs and Therapy</i> , 2007, 21, 423-429.	1.3	49
58	A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. <i>Journal of Hypertension</i> , 2011, 29, 509-519.	0.3	47
59	Heart rate reduction with ivabradine prevents the global phenotype of left ventricular remodeling. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2011, 300, H366-H373.	1.5	47
60	Role of A2A Receptor in the Modulation of Myocardial Reperfusion Damage. <i>Journal of Cardiovascular Pharmacology</i> , 1999, 33, 883-893.	0.8	47
61	Long-term results of coronary artery bypass grafting procedure in the presence of left ventricular dysfunction and hibernating myocardium. <i>European Journal of Cardio-thoracic Surgery</i> , 2001, 20, 937-948.	0.6	46
62	Cardioprotection by nisoldipine: role of timing of administration. <i>European Heart Journal</i> , 1993, 14, 1258-1272.	1.0	43
63	Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. <i>Pharmacological Research</i> , 2007, 56, 42-48.	3.1	42
64	Heart rate reduction with ivabradine improves energy metabolism and mechanical function of isolated ischaemic rabbit heart. <i>Cardiovascular Research</i> , 2009, 84, 72-82.	1.8	42
65	Skeletal muscle myosin heavy chain expression in rats with monocrotaline-induced cardiac hypertrophy and failure. Relation to blood flow and degree of muscle atrophy. <i>Cardiovascular Research</i> , 1998, 39, 233-241.	1.8	41
66	Secondary Prevention of CAD with ACE Inhibitors: A Struggle Between Life and Death of the Endothelium. <i>Cardiovascular Drugs and Therapy</i> , 2010, 24, 331-339.	1.3	41
67	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Heart Failure</i> , 2022, 24, 143-168.	2.9	41
68	ACE Inhibition Modulates Endothelial Apoptosis and Renewal via Endothelial Progenitor Cells in Patients with Acute Coronary Syndromes. <i>American Journal of Cardiovascular Drugs</i> , 2011, 11, 189-198.	1.0	40
69	Comprehensive efforts to increase adherence to statin therapy. <i>European Heart Journal</i> , 2017, 38, ehw628.	1.0	40
70	Reasons for disparity in statin adherence rates between clinical trials and real-world observations: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 230-236.	1.4	39
71	Mechanisms of Remodelling A Question of Life (Stem Cell Production) and Death (Myocyte Apoptosis). <i>Circulation Journal</i> , 2009, 73, 1973-1982.	0.7	38
72	Induction of functional inducible nitric oxide synthase in monocytes of patients with congestive heart failure. Link with tumour necrosis factor- α . <i>European Heart Journal</i> , 1999, 20, 1503-1513.	1.0	37

#	ARTICLE	IF	CITATIONS
73	Protective effect of propionyl-L-carnitine against ischaemia and reperfusion-damage. <i>Molecular and Cellular Biochemistry</i> , 1989, 88, 161-8.	1.4	36
74	Anti-ischaemic effect of ivabradine. <i>Pharmacological Research</i> , 2006, 53, 435-439.	3.1	36
75	Specific Properties and Effect of Perindopril in Controlling the Renin-Angiotensin System. <i>American Journal of Hypertension</i> , 2005, 18, 142-154.	1.0	35
76	Prolonged propionyl-L-carnitine pre-treatment of rabbit: Biochemical, hemodynamic and electrophysiological effects on myocardium. <i>Journal of Molecular and Cellular Cardiology</i> , 1992, 24, 219-232.	0.9	33
77	Effects of iloprost (ZK 36374) on glutathione status during ischaemia and reperfusion of rabbit isolated hearts. <i>British Journal of Pharmacology</i> , 1989, 98, 678-684.	2.7	32
78	Reduction of oxidative stress by carvedilol: role in maintenance of ischaemic myocardium viability. <i>Cardiovascular Research</i> , 2000, 47, 556-566.	1.8	32
79	Abnormalities of Left Ventricular Function in Asymptomatic Patients with Systemic Sclerosis Using Doppler Measures of Myocardial Strain. <i>Journal of the American Society of Echocardiography</i> , 2008, 21, 1257-1264.	1.2	32
80	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. <i>Revista Espanola De Cardiología</i> , 2012, 65, 938.e1-938.e59.	0.6	31
81	Cellular Thiols Redox Status: a Switch for NF- κ B Activation During Myocardial Post-ischaemic Reperfusion. <i>Journal of Molecular and Cellular Cardiology</i> , 2002, 34, 997-1005.	0.9	30
82	Metalloproteinase 2 cleaves in vitro recombinant TRAIL: Potential implications for the decreased serum levels of TRAIL after acute myocardial infarction. <i>Atherosclerosis</i> , 2010, 211, 333-336.	0.4	30
83	Overview of the pharmacological challenges facing physicians in the management of patients with concomitant cardiovascular disease and chronic obstructive pulmonary disease. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 205-211.	1.4	30
84	Ischemic preconditioning, myocardial stunning, and hibernation: Basic aspects. <i>American Heart Journal</i> , 1999, 138, S61-S68.	1.2	29
85	Occurrence and impact of chronic obstructive pulmonary disease in elderly patients with stable heart failure. <i>Respirology</i> , 2013, 18, 125-130.	1.3	26
86	Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2015, 12, 560-567.	0.7	25
87	ACE inhibition with perindopril and biomarkers of atherosclerosis and thrombosis: Results from the PERTINENT study. <i>Atherosclerosis</i> , 2009, 204, 273-275.	0.4	24
88	Plasma sRAGE and N ^ε -(carboxymethyl) lysine in patients with CHF and/or COPD. <i>European Journal of Clinical Investigation</i> , 2013, 43, 562-569.	1.7	23
89	Intermittent v continuous ischemia decelerates adenylate breakdown and prevents norepinephrine release in reperfused rabbit heart. <i>Journal of Molecular and Cellular Cardiology</i> , 1995, 27, 659-671.	0.9	22
90	Effects of treatment strategy on endothelial function. <i>Autoimmunity Reviews</i> , 2010, 9, 840-844.	2.5	22

#	ARTICLE	IF	CITATIONS
91	Effects of endotoxic shock on neuronal NOS and calcium transients in rat cardiac myocytes. <i>Pharmacological Research</i> , 2005, 51, 409-417.	3.1	21
92	Prolonged protective effect of the calcium antagonist anipamil on the ischemic reperfused rabbit myocardium: Comparison with verapamil. <i>Cardiovascular Drugs and Therapy</i> , 1989, 3, 403-412.	1.3	19
93	Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation: experimental studies. <i>Journal of Heart and Lung Transplantation</i> , 1999, 18, 478-487.	0.3	19
94	Echocardiography, Spirometry, and Systemic Acute-Phase Inflammatory Proteins in Smokers with COPD or CHF: An Observational Study. <i>PLoS ONE</i> , 2013, 8, e80166.	1.1	19
95	Role of bradykinin and eNOS in the anti-ischaemic effect of trandolapril. <i>British Journal of Pharmacology</i> , 2001, 133, 145-153.	2.7	17
96	Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-study. <i>European Heart Journal</i> , 2009, 30, 1656-1665.	1.0	17
97	Plasma levels of atrial natriuretic factor (ANF) and urinary excretion of ANF, arginine vasopressin and catecholamines in children with congenital heart disease: effect of cardiac surgery. <i>European Journal of Cardio-thoracic Surgery</i> , 1993, 7, 533-539.	0.6	16
98	Continuous versus intermittent warm blood cardioplegia: Functional and energetics changes. <i>Annals of Thoracic Surgery</i> , 1996, 62, 1172-1179.	0.7	16
99	Non-insulin antidiabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal</i> , 2018, 39, 2274-2281.	1.0	16
100	Selective and specific inhibition with ivabradine: new perspectives for the treatment of cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 959-973.	0.6	15
101	The heart rate story. <i>European Heart Journal Supplements</i> , 2011, 13, C4-C13.	0.0	15
102	Actualizaci3n detallada de las gu3as de la ESC para el manejo de la fibrilaci3n auricular de 2012. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 54.e1-54.e24.	0.6	14
103	Skeletal Muscle Metabolism in Experimental Heart Failure. <i>Journal of Molecular and Cellular Cardiology</i> , 1996, 28, 2263-2273.	0.9	13
104	Relation between energy metabolism, glycolysis, noradrenaline release and duration of ischemia. <i>Molecular and Cellular Biochemistry</i> , 1996, 160-161, 187-194.	1.4	13
105	Effect of thalidomide on the skeletal muscle in experimental heart failure. <i>European Journal of Heart Failure</i> , 2002, 4, 455-460.	2.9	12
106	Specific and selective If inhibition: expected clinical benefits from pure heart rate reduction in coronary patients. <i>Country Review Ukraine</i> , 2005, 7, H16-H21.	0.8	12
107	Revascularization of hibernating myocardium. Rate of metabolic and functional recovery and occurrence of oxidative stress. <i>European Heart Journal</i> , 2002, 23, 1877-1885.	1.0	11
108	Skeletal muscle abnormalities in rats with experimentally induced heart hypertrophy and failure. <i>Basic Research in Cardiology</i> , 2003, 98, 114-123.	2.5	11

#	ARTICLE	IF	CITATIONS
109	Relevance of apoptosis in influencing recovery of hibernating myocardium. <i>European Journal of Heart Failure</i> , 2007, 9, 377-383.	2.9	11
110	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 275-300.	0.8	11
111	Update on management of hypokalaemia and goals for the lower potassium level in patients with cardiovascular disease: a review in collaboration with the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 557-567.	1.4	10
112	Lipid peroxidation during myocardial reperfusion. <i>Molecular and Cellular Biochemistry</i> , 1992, 111, 49-54.	1.4	9
113	Effects of felodipine on the ischemic heart: Insight into the mechanism of cytoprotection. <i>Cardiovascular Drugs and Therapy</i> , 1996, 10, 425-437.	1.3	9
114	Lipid Peroxidation in Normal Pregnancy and Preeclampsia. <i>Advances in Experimental Medicine and Biology</i> , 1994, 366, 420-421.	0.8	9
115	Is Stunning an Important Component of Preconditioning?. <i>Journal of Molecular and Cellular Cardiology</i> , 1996, 28, 2323-2331.	0.9	7
116	In vitro administration of ergothioneine failed to protect isolated ischaemic and reperfused rabbit heart. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 1995, 1270, 173-178.	1.8	6
117	TNF? in patients with congestive heart failure. <i>Basic Research in Cardiology</i> , 2004, 99, 12-17.	2.5	6
118	Impact of remote monitoring on the management of arrhythmias in patients with implantable cardioverter-defibrillator. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 775-781.	0.6	6
119	The combined effect of subcutaneous granulocyte- colony stimulating factor and myocardial contrast echocardiography with intravenous infusion of sulfur hexafluoride on post-infarction left ventricular function, the RIGENERA 2.0 trial: study protocol for a randomized controlled trial. <i>Trials</i> , 2016, 17, 97.	0.7	6
120	Time Dependence of the Cardioprotective Effects of Lercanidipine. <i>Journal of Cardiovascular Pharmacology</i> , 1997, 29, S69-S77.	0.8	5
121	Long-Term Changes in Left Ventricular Mass, Chamber Size and Function after Valve Replacement in Patients with Severe Aortic Stenosis and Depressed Ejection Fraction. <i>Cardiology</i> , 1997, 88, 315-322.	0.6	5
122	Neurohormones, cytokines and programmed cell death in heart failure: a new paradigm for the remodeling heart. <i>Cardiovascular Drugs and Therapy</i> , 2001, 15, 529-537.	1.3	5
123	Preliminary observations on the effects of acute infusion of growth hormone on coronary vasculature and on myocardial function and energetics of an isolated and blood-perfused heart. <i>Journal of Endocrinological Investigation</i> , 2003, 26, RC1-RC4.	1.8	4
124	One Heart, Two Lungs Together Forever. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 174, 962-963.	2.5	4
125	Levels of evidence in the European Society of Cardiology Guidelines: Gaps in knowledge?. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1941-1943.	0.8	4
126	Endothelial Dysfunction in Congestive Heart Failure: Effects of Carvedilol. <i>Heart Failure Reviews</i> , 1999, 4, 53-64.	1.7	3

#	ARTICLE	IF	CITATIONS
127	Pharmacological treatment of chronic systolic heart failure: are we scraping the bottom of the barrel?. <i>Journal of Cardiovascular Medicine</i> , 2010, 11, 893-905.	0.6	3
128	Effects of Lercanidipine on Fe ²⁺ -Induced Mitochondrial Lipid Peroxidation. <i>Journal of Cardiovascular Pharmacology</i> , 1997, 29, S63-S72.	0.8	2
129	Î ² -Adrenergic receptors and intracellular signalling pathway in stunned and non-ischemic regions of pig myocardium. <i>Basic Research in Cardiology</i> , 2001, 96, 388-394.	2.5	2
130	PERTINENT: AUTHORS' RETROSPECTIVE. <i>Cardiovascular Research</i> , 2012, 96, 204-207.	1.8	2
131	GuÃade prÃctica clÃnica sobre el tratamiento de las valvulopatÃas (versiÃn 2012). <i>Revista Espanola De Cardiologia</i> , 2013, 66, 131.e1-131.e42.	0.6	2
132	Future strategies of reverse remodeling prevention of hibernation. <i>Journal of Cardiac Failure</i> , 2002, 8, S542-S548.	0.7	1
133	Incremental Exercise Using Progressive Versus Constant Pedaling Rates. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2011, 31, 303-307.	1.2	1
134	Les liaisons dangereuses and the danger of deductions: The interplay between cardiovascular disease and COVID-19. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1015-1016.	0.8	1
135	Measurement of free malondialdehyde during myocardial ischaemia and reperfusion injury. <i>Journal of Molecular and Cellular Cardiology</i> , 1990, 22, S118.	0.9	0
136	Are neutrophilseutrophils involved in the oxidative stress occurring in man during post-ischaemic reperfusion?. <i>Journal of Molecular and Cellular Cardiology</i> , 1992, 24, 70.	0.9	0
137	A way forward to the elimination of conflict of interest for experts involved in regulatory medicine and guidelines. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 80-81.	1.4	0
138	The dangerous liaison: Coronary and kidney disease. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1610-1611.	0.8	0
139	Diabetes mellitus and chronic kidney disease: A neglected and dangerous liaison. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 1920-1921.	0.8	0
140	Neuroendocrine Control of the Cardiovascular System in Heart Failure. , 2009, , 13-20.		0
141	Evidence Against Malondialdehyde Bound to Cellular Constituents in Phospholipid Peroxidation. <i>Advances in Experimental Medicine and Biology</i> , 1994, 366, 404-406.	0.8	0
142	In Vitro Ergothioneine Administration Failed to Protect Isolated Ischaemic and Reperfused Rabbit Heart. <i>Advances in Experimental Medicine and Biology</i> , 1994, 366, 448-449.	0.8	0